Background: Renal transplant recipients (RTRs) have an increased risk of developing nonmelanoma skin cancer, mainly cutaneous squamous cell carcinoma (cSCC). Two genes (TMC6/EVER1 and TMC8/EVER2), mutated in epidermodysplasia verruciformis (EV) patients with an increased risk of cSCC development, contain numerous single-nucleotide polymorphisms (SNPs). Aim: To evaluate the effect of SNPs in both TMC/EVER genes on the different susceptibilities of RTRs to cSCC. Method: We determined the occurrence of cSCC in 105 RTRs who were transplanted at least 7 years previously and investigated the frequency of 26 SNPs within both TMC/EVER genes in severely affected (n = 16) as well as in nonaffected RTRs (n = 25). Results: Our data did not indicate a significant association between any SNP genotype and risk of cSCC development in RTRs. Conclusion: To clarify the correlation between SNPs in both TMC genes and cSCC development in RTRs, integrated investigations of large cohorts including both RTRs and immunocompetent individuals with consideration of cSCC status, SNP genotype and human papillomavirus status might be necessary.

1.
Lindelof B, Sigurgeirsson B, Gabel H, Stern RS: Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol 2000;143:513-519.
2.
Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S: Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999;40:177-186.
3.
Gallagher MP, Kelly PJ, Jardine M, Perkovic V, Cass A, Craig JC, Eris J, Webster AC: Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-858.
4.
Kovach BT, Stasko T: Skin cancer after transplantation. Transplant Rev (Orlando) 2009;23:178-189.
5.
Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, Valerio F, Rugiu C, Sassi F, Gotti E, Fonte L, Talamini G, Girolomoni G: Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant 2013;13:214-221.
6.
Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA; EPV-HPV-UV-CA group: Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in the Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol 2007;127:1647-1656.
7.
Burger B, Itin PH: Epidermodysplasia verruciformis. Curr Probl Dermatol 2014;45:123-131.
8.
Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579-581.
9.
Castro FA, Ivansson EL, Schmitt M, Juko-Pecirep I, Kjellberg L, Hildesheim A, Gyllensten UB, Pawlita M: Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants to cervical cancer susceptibility. Int J Cancer 2012;130:349-355.
10.
Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M, Rodriguez AC, Sherman ME, Bratti C, Schiffman M, Wacholder S, Burk RD, Herrero R, Chanock SJ, Hildesheim A: Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One 2010;5:e8667.
11.
Johanneson B, Chen D, Enroth S, Cui T, Gyllensten U: Systematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study. Carcinogenesis 2014;35:2084-2088.
12.
Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, Orlow I: Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 2012;132:1471-1478.
13.
Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 1986;6:4650-4656.
14.
Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-963.
15.
Cheng C, Lingyan W, Yi H, Cheng Z, Huadan Y, Xuting X, Leiting X, Meng Y, Shiwei D: Association between TLR2, MTR, MTRR, XPC, TP73, TP53 genetic polymorphisms and gastric cancer: a meta-analysis. Clin Res Hepatol Gastroenterol 2014;38:346-359.
16.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
17.
Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.
18.
Yang J, Liu B, Li W, Xiong H, Qiu H, Fu Q, Chen B, Hu G, Yuan X: Association of p53 and mdm2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC). Cancer Epidemiol 2013;37:629-633.
19.
De Oliveira WR, Rady PL, Grady J, Hughes TK, Neto CF, Rivitti EA, Tyring SK: Association of p53 arginine polymorphism with skin cancer. Int J Dermatol 2004;43:489-493.
20.
McGregor JM, Harwood CA, Brooks L, Fisher SA, Kelly DA, O'Nions J, Young AR, Surentheran T, Breuer J, Millard TP, Lewis CM, Leigh IM, Storey A, Crook T: Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002;119:84-90.
21.
Shastry BS: SNPs: impact on gene function and phenotype. Methods Mol Biol 2009;578:3-22.
22.
Venza M, Catalano T, Visalli M, Venza I, Lentini M, Curia MC, Mariani-Costantini R, Teti D: Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. J Invest Dermatol 2010;130:1719-1725.
23.
Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M: The ever proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009;73:348-370.
24.
Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L, Tessari G, Feltkamp MC, de Koning MN, Quint WG, Waterboer T, Pawlita M, Weissenborn S, Wieland U, Pfister H, Stockfleth E, Nindl I, Abeni D, Schegget JT, Bouwes Bavinck JN: A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011;11:1498-1508.
25.
Purdie KJ, Surentheran T, Sterling JC, Bell L, McGregor JM, Proby CM, Harwood CA, Breuer J: Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 2005;125:98-107.
26.
Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, Bavinck JN, Perry AE, Spencer SK, Daling J, Green AC, Pawlita M: Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ 2010;341:c2986.
27.
Keller B, Braathen LR, Marti HP, Hunger RE: Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly 2010;140:w13036.
28.
Berg D, Otley CC: Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002;47:1-17, quiz 18-20.
29.
Gaud G, Guillemot D, Jacob Y, Favre M, Vuillier F: EVER2 protein binds TRADD to promote TNF-alpha-induced apoptosis. Cell Death Dis 2013;4:e499.
30.
Hohenstein E, Rady PL, Hergersberg M, Huber AR, Tyring SK, Bregenzer T, Streit M, Itin P: Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A→T polymorphism in the TMC8/EVER2 gene. Dermatology 2009;218:114-118.
31.
Arnold AW, Burger B, Kump E, Rufle A, Tyring SK, Kempf W, Hausermann P, Itin PH: Homozygosity for the c.917A → T (p.N306l) polymorphism in the EVER2/TMC8 gene of two sisters with epidermodysplasia verruciformis Lewandowsky-Lutz originally described by Wilhelm Lutz. Dermatology 2011;222:81-86.
32.
Patel AS, Karagas MR, Pawlita M, Waterboer T, Nelson HH: Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma: a case-control study. Int J Cancer 2008;122:2377-2379.
33.
Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM: Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-297.
34.
Madeleine MM, Carter JJ, Johnson LG, Wipf GC, Davis C, Berg D, Nelson K, Daling JR, Schwartz SM, Galloway DA: Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants. Cancer Med 2014;3:1440-1447.
35.
Zuo YG, Ma D, Zhang Y, Qiao J, Wang B: Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006;44:153-159.
36.
O'Connor DP, Kay EW, Leader M, Atkins GJ, Murphy GM, Mabruk MJ: p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 2001;54:539-542.
37.
Liu T, Lei Z, Pan Z, Chen Y, Li X, Mao T, He Q, Fan D: Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma. Tumour Biol 2014;35:3899-3903.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.